NL-OMON48348
Recruiting
Not Applicable
Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer. - PRIMUS
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- MAASTRO clinic
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Local relapse of prostate cancer, who is candidate for a salvage HDR
- •\- 18 years or older
- •\- Willing and able to comply with the study prescriptions.
- •\- Before patient registration, written informed consent must be given according
- •to ICH/GCP, and national/local regulations.
Exclusion Criteria
- •\- Not eligible for proposed (HDR brachytherapy) treatment.
- •\- No compliance
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Immune Profiling After HDR in Local Relapsed Prostate CancerProstate CancerPD-L1NCT04247217Maastricht Radiation Oncology10
Not yet recruiting
Not Applicable
Analysis of prostrate-specific immunity in stage III and IV prostate cancer patientsprostate cancer10038597NL-OMON32487KI-AV50
Not yet recruiting
Phase 2
A continence promotion intervention involving a pelvic floor muscle rehabilitation exercise program to reduce lower urinary tract, lower bowel symptoms and erectile dysfunction in men receiving radiation therapy with or without androgen deprivation therapy (ADT): A Pilot StudyProstate Cancer TreatmentLower Urinary Tract sequelae to radiation therapy with or without androgen deprivation therapyLower Bowel Dysfunction as sequelae to radiation therapy with or without androgen deprivation therapyErectile Dysfunction as sequelae to radiation therapy with or without androgen deprivation therapyCancer - ProstatePhysical Medicine / Rehabilitation - PhysiotherapyRenal and Urogenital - Other renal and urogenital disordersACTRN12612000527864niversity of Newcastle40
Withdrawn
Phase 2
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerCastration Resistant Prostate CancerNCT05445882National Cancer Institute (NCI)
Completed
Not Applicable
Detecting prostate cancer by the intracellular presence of prostate-specific antigen in macrophages, detected in peripheral blood samples by a flow cytometric technique.benign prostate hypertrophiaprostate carcinoma10038364NL-OMON37430Atrium Medisch Centrum150